These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 35427743)
1. LRRK2 as a target for modulating immune system responses. Russo I; Bubacco L; Greggio E Neurobiol Dis; 2022 Jul; 169():105724. PubMed ID: 35427743 [TBL] [Abstract][Full Text] [Related]
2. LRRK2 and the Immune System. Dzamko NL Adv Neurobiol; 2017; 14():123-143. PubMed ID: 28353282 [TBL] [Abstract][Full Text] [Related]
3. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. Lee H; James WS; Cowley SA Biochem Soc Trans; 2017 Feb; 45(1):131-139. PubMed ID: 28202666 [TBL] [Abstract][Full Text] [Related]
9. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255 [TBL] [Abstract][Full Text] [Related]
10. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. Tsafaras G; Baekelandt V Neurobiol Dis; 2022 Oct; 172():105806. PubMed ID: 35781002 [TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years. Filippini A; Gennarelli M; Russo I Biochem Soc Trans; 2021 Jun; 49(3):1375-1384. PubMed ID: 33960369 [TBL] [Abstract][Full Text] [Related]
14. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Shirvan JC; Cedarbaum JM; Orr-Urtreger A; Regev K; Shenhar-Tsarfaty S; Mirelman A J Parkinsons Dis; 2021; 11(3):1285-1296. PubMed ID: 33998549 [TBL] [Abstract][Full Text] [Related]
15. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K; Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032 [TBL] [Abstract][Full Text] [Related]
16. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. Thakur G; Kumar V; Lee KW; Won C Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011337 [TBL] [Abstract][Full Text] [Related]
17. Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons. Schildt A; Walker MD; Dinelle K; Miao Q; Schulzer M; O'Kusky J; Farrer MJ; Doudet DJ; Sossi V J Parkinsons Dis; 2019; 9(1):121-139. PubMed ID: 30452424 [TBL] [Abstract][Full Text] [Related]
18. Pathological Functions of LRRK2 in Parkinson's Disease. Jeong GR; Lee BD Cells; 2020 Nov; 9(12):. PubMed ID: 33266247 [TBL] [Abstract][Full Text] [Related]
19. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855 [TBL] [Abstract][Full Text] [Related]
20. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. Wallings RL; Herrick MK; Tansey MG Front Neurosci; 2020; 14():443. PubMed ID: 32508566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]